, Tracking Stock Market Picks
Enter Symbol:

Mkt Outperform
down 84.59 %

CELSION CORP (CLSN) rated Mkt Outperform with price target $6 by Rodman & Renshaw

Posted on: Wednesday,  Oct 26, 2011  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform CELSION CORP (NASDAQ: CLSN) on 10/26/2011, when the stock price was $12.92.
Since then, CELSION CORP has lost 84.59% as of 01/19/2016's recent price of $1.99.
If you would have followed this Rodman & Renshaw's recommendation on CLSN, you would have lost 84.59% of your investment in 1546 days.

Celsion Corporation (Celsion) is an oncology drug development company focused on developing drugs for the treatment of various cancer indications. The Company?s product ThermoDox is evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer (RCW). ThermoDox is a liposomal encapsulation of doxorubicin, an oncology drug for the treatment of a range of cancers.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/26/2011 8:25 AM Buy
12.92 27.00
as of 12/30/2011
1 Week down  -3.40 %
1 Month down  -25.43 %
3 Months down  -40.76 %
1 YTD down  -40.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy